2018
918TiP EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
Rosenberg J, Balar A, O’Donnell P, Heath E, Hahn N, Cavazos N, Melhem-Bertrandt A, Petrylak D. 918TiP EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. Annals Of Oncology 2018, 29: viii326-viii327. DOI: 10.1093/annonc/mdy283.127.Peer-Reviewed Original ResearchEV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
Rosenberg J, Heath E, O'Donnell P, Hahn N, Balar A, Gartner E, Melhem-Bertrandt A, Petrylak D. EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. Journal Of Clinical Oncology 2018, 36: tps4590-tps4590. DOI: 10.1200/jco.2018.36.15_suppl.tps4590.Peer-Reviewed Original Research805 EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
Rosenberg J, Balar A, O’Donnell P, Heath E, Hahn N, Gartner E, Melhem-Bertrandt A, Petrylak D. 805 EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. European Urology Open Science 2018, 17: e1152. DOI: 10.1016/s1569-9056(18)31640-3.Peer-Reviewed Original Research
2004
A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC)
Raftopoulos H, Escudier B, Renshaw G, Lara P, Dutcher J, Nanus D, Petrylak D, Sacris L. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal Of Clinical Oncology 2004, 22: 4629-4629. DOI: 10.1200/jco.2004.22.14_suppl.4629.Peer-Reviewed Original ResearchA phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC)
Raftopoulos H, Escudier B, Renshaw G, Lara P, Dutcher J, Nanus D, Petrylak D, Sacris L. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal Of Clinical Oncology 2004, 22: 4629-4629. DOI: 10.1200/jco.2004.22.90140.4629.Peer-Reviewed Original Research